Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10307746 | 0.85 | MAPT (0.53) | MAPK1ALDH1A1SMN1; SMN2CYP2C19LMNA | |
| SCHEMBL15024656 | 0.76 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MAPT | |
| SCHEMBL16282701 | 0.75 | ALDH1A1 (0.49) | MAPK1ALDH1A1PKMSMN1; SMN2CYP1A2 | |
| SCHEMBL2302450 | 0.75 | SMN1; SMN2 (0.66) | MAPK1ALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| Cpi 613 SCHEMBL13333201 | 0.75 | CYP2C19 (0.59) | MAPK1ALDH1A1SMN1; SMN2CYP2C19LMNA | |
| Cpi 613 SCHEMBL1062218 | 0.75 | CYP2C19 (0.59) | MAPK1ALDH1A1SMN1; SMN2CYP2C19LMNA | |
| SCHEMBL22299081 | 0.74 | CYP2C19 (0.58) | MAPK1ALDH1A1SMN1; SMN2CYP2C19LMNA | |
| SCHEMBL17381514 | 0.74 | CYP2C19 (0.58) | MAPK1ALDH1A1SMN1; SMN2CYP2C19LMNA | |
| SCHEMBL9237645 | 0.74 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MAPT | |
| SCHEMBL2960008 | 0.74 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3775325-B1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-08-28 | — | — | EP | claimed |
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | BASF SE (DE) | 2024-08-06 | — | — | US | claimed |
| CN-111918985-B | Composition for tin-silver alloy electroplating comprising complexing agent | 巴斯夫欧洲公司 | 2024-02-02 | — | — | CN | claimed |
| EP-3775325-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-02-17 | — | — | EP | claimed |
| US-20210025070-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-01-28 | — | — | US | claimed |
| WO-2019185468-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2019-10-03 | — | — | WO | claimed |
| EP-3775325-B1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-08-28 | — | — | EP | disclosed |
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | BASF SE (DE) | 2024-08-06 | — | — | US | disclosed |
| CN-111918985-B | Composition for tin-silver alloy electroplating comprising complexing agent | 巴斯夫欧洲公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3775325-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-20210025070-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210025070-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-01-28 | — | — | US | disclosed |
| CN-111918985-A | Composition for tin-silver alloy electroplating comprising complexing agent | 巴斯夫欧洲公司 | 2020-11-10 | — | — | CN | disclosed |
| WO-2019185468-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019185468-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | SCN11A, GRIA3, NR3C1 | HTT 2093/4885MAPK1 1998/4885TP53 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.